Acadia Pharmaceuticals has announced disappointing results from its Phase 3 COMPASS trial, which evaluated the efficacy of intranasal carbetocin in treating hyperphagia in Prader-Willi syndrome. The failure to meet the primary endpoint raises significant questions about the drug’s potential in this patient population and underscores the challenges in developing effective treatments for rare diseases.
SAN DIEGO–(BUSINESS WIRE)–Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin (ACP-101) in patients with hyperphagia in Prader-Willi syndrome (PWS). Intranasal carbetocin did not demonstrate a statistically significant improvement over placebo on the study’s primary endpoint, change from baseline to Week 12 on the Hyperphagia Questionnaire for Clinical Trials (HQ-CT), nor was
Source: Original Press Release